IP Library › Granted Patent US 12,622,915
Granted Patent B2
US 12,622,915 · App. 18/044,805 · Granted May 12, 2026

Methods of treating PDE IV-mediated diseases or conditions

Inventor: Vuk Koprivica (Bethesda, MD)
Assignee: VANDA PHARMACEUTICALS INC.
A61K31/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,622,915
App. No.
18/044,805
Granted
May 12, 2026
Kind
B2
Abstract

The disclosure provides methods and compositions for the treatment of PDE IV-mediated diseases or conditions, including inflammatory diseases or conditions, using a compound of Formula (I) or a pharmaceutically acceptable salt thereof:

Claims (24)

1 . A method for treatment of a patient with a phosphodiesterase IV (PDEIV)-mediated disease or condition that is psoriasis, atopic dermatitis, contact dermatitis, seborrheic dermatitis, stasis dermatitis, morphea, Behçet's Syndrome, lupus, alopecia, vitiligo, acne, lichen planus, uveitis, Prurigo nodularis, or discoid lupus erythematosus, comprising administering to said patient an amount of a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, effective to treat said disease or condition.

2 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is psoriasis.

3 . The method of claim 2 , wherein the PDEIV-mediated disease or condition is plaque psoriasis.

4 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is atopic dermatitis.

5 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is contact dermatitis.

6 . The method of claim 1 , wherein the patient is a human.

7 . The method of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered as a pharmaceutical composition comprising said compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8 . The method of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered topically, orally, perorally, as a suppository, intravenously, parenterally, intraperitoneally, intramuscularly, intralesionally, intrathecally, intranasally, or subcutaneously.

9 . The method of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered topically.

10 . The method of claim 1 , wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

11 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is seborrheic dermatitis.

12 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is stasis dermatitis.

13 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is morphea.

14 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is Behçet's Syndrome.

15 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is lupus.

16 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is alopecia.

17 . The method of claim 16 , wherein the PDEIV-mediated disease or condition is frontal fibrosing alopecia.

18 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is vitiligo.

19 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is acne.

20 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is lichen planus.

21 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is uveitis.

22 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is Prurigo nodularis.

23 . The method of claim 1 , wherein the PDEIV-mediated disease or condition is discoid lupus erythematosus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2023
From: KOPRIVICA, VUK
To: VANDA PHARMACEUTICALS INC.
Reel/Frame 062942/0551 →
Continuity (2)
Provisional Application 63076774 · Sep 10, 2020
Related Publication 20230364100A1 · Nov 16, 2023
References Cited (53)
US 7153854B2 · Abe et al. · 2006 [cited by applicant]
US 10604492B2 · Verkman et al. · 2020 [cited by applicant]
US 11839616B2 · Verkman et al. · 2023 [cited by applicant]
US 20060089375A1 · Allen et al. · 2006 [cited by applicant]
US 20080027112A1 · Govek et al. · 2008 [cited by applicant]
CN 101495454A · 2009 [cited by applicant]
JP 2019505502A · 2019 [cited by applicant]
JP 2020531511A · 2020 [cited by applicant]
RU 2328499C2 · 2008 [cited by applicant]
WO 2004024728A2 · 2004 [cited by applicant]
WO 2007142929A2 · 2007 [cited by applicant]
WO 2017112951A1 · 2017 [cited by applicant]
WO 2019040919A1 · 2019 [cited by applicant]
WO 2021113580A1 · 2021 [cited by applicant]
Harkevich, Farmakologija, [English: “Pharmacology”], 10th edition, Moscow, GJeOTAR-Media, pp. 73-74, 2010. [cited by applicant]
Olisova et al., Ingibitor fosfodijesterazy-4 v lechenii, [English “Phosphodiesterase-4 inhibitor in treatment”], Vestnik Dermatologii i Venerologii, 95(2):74-80, 2019. (English Abstract Submitted). [cited by applicant]
Sadrai Z. et al., PDE4 inhibition suppresses IL-17-associated immunity in dry eye disease, Investigative ophthalmology & visual science, 53(7):3584-3591, 2012. [cited by applicant]
Zhulenko et al., Farmakologija, [English: “Pharmacology”], Moscow, KolosS, pp. 34-35, 2008. [cited by applicant]
Edelson et al., Poster: 303, Cilomilast (Ariflo®), A Potent, Selective Inhibitor Of Phosphodiesterase 4, Improves Lung Function In COPD Patients: Results of a 6-Month Trial, ATS 98th International Conference, May 17-23,… [cited by applicant]
Abelson, Md, Mark B., et al., “Conjunctival Allergen Challenge”, Arch Ophthalmol, Jan. 1990, vol. 108, pp. 84-88. [cited by applicant]
Abelson, Md, Mark B., et al., “Conjunctival Allergen Challenge: Models in the Investigation of Ocular Allergy”, Current Allergy and Asthma Reports, (2003), vol. 3, pp. 363-368. [cited by applicant]
Banner, Katharine H., et al., “PDE4 Inhibition: a Novel Approach for the Treatment of Inflammatory Bowel Disease”, Trends in Pharmalogical Sciences, Aug. 2004, vol. 25, No. 8, pp. 430-436. [cited by applicant]
Barnes, Peter J., “New Drugs for Asthma”, Nature Reviews, Drug Discovery, Oct. 2004, vol. 3, pp. 831-844. [cited by applicant]
Bäumer, Wolfgang et al., “Effects of the Phosphodiesterase 4 Inhibitors SB 207499 and AWD 12-281 on the Inflammatory Reaction in a Model of Allergic Dermatitis”, European Journal of Pharmacology, 2002, vol. 446, pp. 195… [cited by applicant]
Bender, Andrew T., et al., “Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use”, Pharmacological Reviews, 2006, vol. 58, No. 3, pp. 488-520. [cited by applicant]
Borker, Rohit D., et al., Effect of Cilomilast on Quality of Life Improvement/Deterioration and Non-Drug Costs in Patients with Chronic Obstructive Pulmonary Disease, Chest, 2003, vol. 124, No. 4, p. 170S. [cited by applicant]
Burnouf, Catherine et al., Recent Advances of PDE4 Inhibitors as Immunoregulators and Anti-Inflammatory Drugs, Current Pharmaceutical Design, 2002, vol. 8, 1255-1296. [cited by applicant]
Doherty, Annette M., “Phosphodiesterase 4 Inhibitors as Novel Anti-Inflammatory Agents”, Current Opinion in Chemical Biology, 1999, vol. 3, pp. 466-473. [cited by applicant]
Dyke, Hazel, J., et al., “Update on the Therapeutic Potential of PDE4 Inhibitors,” Expert Opinion Investigation on Drugs, 2002, 11, No. 1, pp. 1-13. [cited by applicant]
Gamanuma, Michiko et al., “Comparison of Enzymatic Characterization and Gene Organization of Cyclic Nucleotide Phosphodiesterase 8 Family in Humans”, Cellular Signalling, 2003, vol. 15, pp. 565-574. [cited by applicant]
Giembycz, Mark A., “Phosphodiesterase 4 Inhibitors and the Treatment of Asthma”, Drugs, Feb. 2000, vol. 59, No. 2, pp. 193-212. [cited by applicant]
Gillespie, Peter G., et al., “Inhibition and Stimulation of Photoreceptor Phosphodiesterases by Dipyridamole and M&B 22,948”, Molecular Pharmacology, vol. 36, pp. 773-781. [cited by applicant]
Govek, Steven P., et al., “Water-soluble PDE4 Inhibitors for the Treatment of Dry Eye,” Bioorganic & Medicinal Chemistry Letters, 2010, vol. 20, No. 9, pp. 2928-2932. [cited by applicant]
Griffiths, C.E.M., et al., “Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for treatment of atopic dermatitis”, Br. J. Dermatol., 2… [cited by applicant]
Huang, Zheng et al., “The Next Generation of PDE4 Inhibitors”, Current Opinion of Chemical Biology, 2001, vol. 5, pp. 432-438. [cited by applicant]
Krishna, Ganesh et al., “New Therapies for Chronic Obstructive Pulmonary Disease,” Expert Opinion on Investigational Drugs, 2004, vol. 13, No. 3, pp. 255-267. [cited by applicant]
Kumar, Anil, et al., “Analgesic and Anti-Inflammatory Effects of Phosphodiesterase Inhibitors”, Indian Journal of Experimental Biology, Jan. 2000, vol. 38, pp. 26-30. [cited by applicant]
Lee, Sujin et al., “Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases11;” J. Med. Che… [cited by applicant]
Li, Heng et al., “Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases,” Frontiers in Pharmacology, vol. 9, Article 1048, Oct. 17, 2018, pp. 1-21. [cited by applicant]
Lipworth, Brian J., “Phosphodiesterase-4 Inhibitors for Asthma and Chronic Obstructive Pulmonary Disease”, New Drug Classes, Lancet, 2005, vol. 365, pp. 167-175. [cited by applicant]
O'Donnell, James M., et al. Antidepressant Effects of Inhibitors of CAMP Phosphodiesterase (PDE4), Trends in Pharmacological Sciences, Mar. 2004, vol. 25, No. 3, pp. 158-163. [cited by applicant]
O'Donnell, James M., “William Harvey Research Conference on PDE Inhibitors: Drugs with an Expanding Range of Therapeutic Uses,” Expert Opinion Investigation in Drugs, 2000, vol. 9, No. 3, pp. 621-625. [cited by applicant]
Press, Neil J., et al., “2 PDE4 Inhibitors—A Review of the Current Field”, Progress in Medicinal Chemistry, 2009, vol. 47, pp. 37-74. [cited by applicant]
Renau, Thomas E., “The Potential of Phosphodiesterase 4 Inhibitors for the Treatment of Depression: Opportunities and Challenges”, Current Opinion in Investigational Drugs, 2004, vol. 5, No. 1, pp. 34-39. [cited by applicant]
Richter, Wito et al., “Identification of Inhibitor Binding Sites of the cAMP-Specific Phosphodiesterase 4”, Cellular Signalling, 2001, vol. 13, pp. 287-297. [cited by applicant]
Roos, Thomas C., et al., “Recent Advances in Treatment Strategies for Atopic Dermatitis”, Drugs, 2004, vol. 64, No. 23, pp. 2639-2666. [cited by applicant]
Rotella, D. P., “Phosphodiesterases”, Comprehensive Medicinal Chemistry II, 2007, pp. 919-957. [cited by applicant]
Sasaki, Takashi et al., “Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase”, Biochemical and Biophysical Research Communications, 2000, vol. 271, No. 3, pp. 575-583. [cited by applicant]
Spina, Domenico, “Phosphodiesterase-4 Inhibitors in the Treatment of Inflammatory Lung Disease,” Drugs, 2003, vol. 63, No. 23, pp. 2575-2594. [cited by applicant]
Wolda, Sharon L., “PDE4 Inhibitors and Chronic Obstructive Pulmonary Disease”, Emerging Drugs, 2000, vol. 5, No. 3, pp. 309-319. [cited by applicant]
Zhang, Han-Ting et al., “Effects of Rolipram on Scopolamine-Induced Impairment of Working and Reference Memory in the Radial-Arm Maze Tests in Rats”, Psychopharmacology, 2000, vol. 150, pp. 311-316. [cited by applicant]
“Kratkij kurs molekuljarnoj farmakologii” in Russian, [English: “A Short Course of Molecular Pharmacology”] edited by P.V. Sergeev, Moscow, 1975, p. 10. (English Translation provided). [cited by applicant]
“Klinicheskaja farmakokinetika” in Russian, [English: “Clinical Pharmacokinetics”], L.E. Kholodov et al., Moscow, “Medicine”, 1985, pp. 83-98, 134-138, 160, 378-380. (Machine Translation provided). [cited by applicant]